Lumida
/INBX
⌘K
Inhibrx Biosciences Inc

Inhibrx Biosciences Inc

INBX
$109.27USD-1.93%-2.15 today

MARKET CAP

1.6B

P/E (TTM)

FWD P/E

DAY RANGE

$109 – $115

52W RANGE

$26
$155

AI Summary

Stalk
StalkMedium

INBX displayed a Bearish Exhaustion candle at a key support area, signaling a potential bottoming bounce into the 50-day SMA and 200-day SMA zone. While medium-term bias remains bullish under the higher-highs higher-lows regime and exhaustion signal, price currently sits below the 9- and 20-period EMAs and requires a clearer acceptance of the support zone. Execution will be deferred until pullbacks into this structural support are reliably held.

  • FDA accepted ozekibart BLA for oncology; review set April 14, 2027.
  • $325 M debt facility (Oxford Finance) with $100 M funded in July for R&D.
  • Q2 2026 net loss $36.7 M ($2.34/share) underscores weak profitability.
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2024FY 2025TREND
Sales, Adj.$200,000$1.3M
YoY %+550.0%
P / Sales1153.8x941.1x
EV / Sales626.7x952.1x
Gross Profit, Adj.$200,000$1.3M
YoY %+550.0%
Margin %100.0%100.0%
EV / Gross Profit626.7x952.1x
EBITDA, Adj.$-329.2M$-132.5M
YoY %+59.7%
Margin %-164581.5%-10195.5%
EV / EBITDA-0.4x-9.3x
EBIT$-331.4M$-135.0M
YoY %+59.3%
Margin %-165724.0%-10386.5%
EV / EBIT-0.4x-9.2x
Net Income$1.7B$-140.1M
YoY %-108.3%
Net Margin843786.0%-10773.5%
EPS (GAAP)$112.62-$9.04
YoY %-108.0%